Ethyl pyruvate (EP) has been shown to have significant anti-inflammatory activities. Here, we explore the therapeutic effects of EP administration on tumor growth and metastasis in orthotopic implantation human gastric cancer models in severe combined immunodeficiency (SCID) mice. After SCID mice were treated with EP, the tumor growth and liver metastasis from gastric cancer were investigated and its possible molecular mechanisms were further studied. As a result, it was found that EP could inhibit tumor growth and liver metastasis of gastric cancer, and reduce tumor lymphangiogenesis indicated by lymphatic microvessel density (LVD) in gastric cancer and metastatic liver tumor. Also, EP decreased the expression of high mobility group box-B1 (HMGB1), receptor for advanced glycation endproducts (RAGE), vascular endothelial growth factor (VEGF) and membrane type-1 matrix metalloprotease (MT1-MMP) in gastric cancer and metastatic liver tumor, but it exerted no effect on expression of nuclear factor-kappa B (NF-κB). Taken together, we suggest that the new application of EP could be a therapeutic option in the treatment of gastric cancer and metastatic liver tumor.
ParkinDMBrayFFerlayJ. Global cancer statistics, 2002. CA Cancer J Clin2005; 55:74–108.
2.
TajimaYYamazakiKMakinoR. Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: Clinicopathologic significance and genetic background. Clin Cancer Res2006; 12:6469–79.
3.
ChoiJLeeMKOhKH. Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line. Tumori2011; 97:196–202.
4.
TangDKangRZehHJ3rdLotzeMT. High-mobility group box 1 and cancer. Biochim Biophys Acta2010; 1799:131–40.
5.
ChungHWLeeSGKimHHongDJChungJBStroncekDLimJB. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med2009; 7:38.
6.
HuttunenHJRauvalaH. Amphoterin as an extracellular regulator of cell motility: From discovery to disease. J Intern Med2004; 255:351–66.
7.
KuniyasuHOueNWakikawaA. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol2002; 196:163–70.
8.
JingRRCuiMSunBL. Tissue-specific expression profiling of receptor for advanced glycation end products and its soluble forms in esophageal and lung cancer. Gent Test Mol Biomarkers2010; 14:355–61.
9.
SasahiraTAkamaYFujiiK. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Archiv2005; 446:411–15.
10.
KostovaNZlatevaSUgrinovaI. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem2010; 337:251–58.
11.
IshiguroHNakaigawaNMiyoshiY. RAGE and its ligand amphoterin are over expressed and associated with prostate cancer development. Prostate2005; 64:92–100.
12.
LeeBLLeeHSJungJChoSJChungHYKimWHJinYWKimCSNamSY. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res2005; 11:2518–25.
13.
MinoKOzakiMNakanishiK. Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Sci2011; 102:1052–8.
ChungKYParkJJKimYS. The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc2008; 40:2136–8.
LimSCChoiJEKimCH. Ethyl pyruvate induces necrosis-to-apoptosis switch and inhibits high mobility group box protein 1 release in A549 lung adenocarcinoma cells. Int J Mol Med2007; 20:187–92.
18.
GnanasekarMThirugnanamSRamaswamyK. Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis. Int J Oncol2009; 34:425–31.
19.
ArumugamTRamachandranVLogsdonCD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst2006; 98:1806–18.
20.
TurovskayaFoellDSinhaP. RAGE carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis2008; 29:2035–43.
21.
SpillerSELogsdonNJDeckardLASontheimerH. Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo. BMC Cancer2011; 11:136.
22.
TangDKangRZehHJ3rdLotzeMT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal2011; 14:1315–35.
23.
KösemMTuncerIKotanCIbiloğluIOztürkMTürkdoğanMK. Significance of VEGF and microvascular density in gastric carcinoma. Hepatogastroenterology2009; 56:1236–40.
24.
ZhuBLuLCaiWYangXLiCYangZZhanWMaJXGaoG. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther2007; 6:3297–306.
25.
UedaJKajitaMSuenagaNFujiiKSeikiM. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: Importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene2003; 22:8716–22.
26.
TemmaTSanoKKugeYKamihashiJTakaiNOgawaYSajiH. Development of a radiolabeled probe for detecting membrane type-1 matrix metalloproteinase on malignant tumors. Biol Pharm Bull2009; 32:1272–7.
27.
SasahiraTKiritaTBhawalUKIkedaMNagasawaAYamamotoKKuniyasuH. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch2007; 450:287–95.
28.
DuttaSWangFQWuHSMukherjeeTJFishmanDA. The NF-κB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). Gynecol Oncol2011; 123:129–37.
29.
QiuJXuJZhengYWeiYZhuXLoEHMoskowitzMASimsJR. HMGB1 promotes MMP-9 upregulation through TLR4 after cerebral ischemiaStroke2010; 41:2077–82.
30.
Bennett-GuerreroESwaminathanMGrigoreAM. A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth2009; 23:324–29.
